Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma

References

• Coit D, Ferrone C. Recurrent regional metastases of melanoma. In: Balch CM, Houghton AN, Sober AJ, et al. editors. Cutaneous melanoma. 5th ed. Florida: CRC Press; 2009. p. 487–498.
   Google Scholar
• Gershenwald JE. CANCER: targeting lymphatic metastasis. Science. 2002;296(5574):1811–1812.
   PubMed Web of Science ®Google Scholar
• Zbytek B, Carlson JA, Granese J, et al. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3(5):569–585.
   PubMedGoogle Scholar
• Heenan PJ, Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg. 1999;52(3):209–213.
   PubMedGoogle Scholar
• McCarthy WH. Melanoma: margins for error - another view. ANZ J Surg. 2002;72(4):304–306.
   PubMed Web of Science ®Google Scholar
• Wilmott J, Haydu L, Bagot M, et al. Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathol. 2012;61(5):889–898.
   PubMed Web of Science ®Google Scholar
• Weddell JC, Chen S, Imoukhuede PI. VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways. NPJ Syst Biol Appl. 2017;4:1. doi: 10.1038/s41540-017-0037-9. eCollection 2018.
   PubMedGoogle Scholar
• Read RL, Haydu L, Saw RPM, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2014;22(2):475–481.
   PubMedGoogle Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Sloot S, Speijers MJ, Bastiaannet E, et al. Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. Cancer Treat Rev. 2016;45:120–128.
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–1317.
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.
   PubMed Web of Science ®Google Scholar
• CL D Jr., Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194(1):108–112.
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol. 1986;12(2):175–180.
   PubMedGoogle Scholar
• Rao UN, Ibrahim J, Flaherty LE, et al. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of eastern cooperative oncology group trial E1690. J Clin Oncol. 2002;20(8):2053–2057.
   PubMed Web of Science ®Google Scholar
• Reintgen DS, Cox C, Slingluff CL, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg. 1992;28(1):45–49.
   PubMed Web of Science ®Google Scholar
• Soong S-J, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67(4):228–233.
   PubMed Web of Science ®Google Scholar
• Dalal KM, Patel A, Brady MS, et al. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(6):1934–1942.
   PubMed Web of Science ®Google Scholar
• Weide B, Faller C, Buttner P, et al. Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS One. 2013;8(4):e63137.
   PubMed Web of Science ®Google Scholar
• Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222.
   PubMed Web of Science ®Google Scholar
• Beasley GM, Speicher P, Sharma K, et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014;218(4):686–692.
   PubMed Web of Science ®Google Scholar
• Beasley GM, Hu Y, Youngwirth L, et al. Sentinel lymph node biopsy for recurrent melanoma: a multicenter study. Ann Surg Oncol. 2017;24(9):2728–2733.
   PubMed Web of Science ®Google Scholar
• Nijhuis AAG, de AO, Santos FID, et al. Sentinel node biopsy in melanoma patients with a local recurrence or in-transit metastasis. Ann Surg Oncol. 2019. [Epub ahead of print].
   Google Scholar
• Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European organization for research and treatment of cancer malignant melanoma cooperative group protocol 18832, the world health organization melanoma program trial 15, and the North American perfusion group southwest oncology group-8593. J Clin Oncol. 1998;16(9):2906–2912.
   PubMedGoogle Scholar
• Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589–597.
   PubMed Web of Science ®Google Scholar
• Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017;82:171–183.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Lee SJ, Yip W. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10;35(8):885–892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.
   Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Kong BY, Carlino MS, Menzies AM. Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Manage. 2016;3(1):33–45.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Larkin JMG, Yan Y, McArthur GA, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol. 2015;33(15_suppl):9006.
   Web of Science ®Google Scholar
• Dummer R, Schadendorf D, Hauschild A, et al. Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. Ann Oncol. 2018;29(Suppl8):viii445.
   Google Scholar
• Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. J Clin Oncol. 2018;36(35):3441–3449.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823.
   Google Scholar
• Carlino MS, Long GV, Kefford RF, et al. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Crit Rev Oncol Hematol. 2015;96(3):385–398.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–213.
   PubMed Web of Science ®Google Scholar
• Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–613.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob -J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. LBA8_PRAdjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). Ann Oncol. 2017;28(suppl_5).
   PubMedGoogle Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Thompson JF. Local and regional therapies for melanoma: many arrows in the quiver. J Surg Oncol. 2014;109(4):295.
   PubMed Web of Science ®Google Scholar
• Middleton M, Hauschild A, Thomson D, et al. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon- 2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol. 2007;18(10):1691–1697.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob -J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581–2587.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636.
   PubMed Web of Science ®Google Scholar
• Daud A, Gill J, Kamra S, et al. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):3. doi: 10.1186/s13045-016-0369-8.
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Tie EN, Lai-Kwon JE, Na L, et al. Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. J Clin Oncol. 2019;37(Suppl 15):9583.
   Google Scholar
• Reinhold RB, Lokich JJ. Electrocoagulation: palliative surgery to control metastatic cutaneous malignancy. J Surg Oncol. 1979;11(3):207–212.
   PubMed Web of Science ®Google Scholar
• Fletcher JN, Mew D, DesCôteaux J-G. Dissemination of melanoma cells within electrocautery plume. Am J Surg. 1999;178(1):57–59.
   PubMed Web of Science ®Google Scholar
• Tanaka S. Immunological aspects of cryosurgery in general surgery. Prog Clin Biol Res. 1982;107:799–814.
   PubMedGoogle Scholar
• Grotmann P, Ernst K, Hundeiker M. Kryochirurgie bei multiplen kutanen melanommetastasen. Z Hautkr. 1991;66:385–389.
   Google Scholar
• Strobbe LJA, Nieweg OE, Kroon BBR. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. EJSO. 1997;23(5):435–438.
   PubMedGoogle Scholar
• Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg. 2004;91(7):893–895.
   PubMed Web of Science ®Google Scholar
• Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci. 2008;24(3):411–414.
   PubMed Web of Science ®Google Scholar
• Austin E, Mamalis A, Ho D, et al. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res. 2017;309(4):229–242.
   PubMed Web of Science ®Google Scholar
• Chan LKW, Quaba AA. Improving the quality of life in melanoma – the role of the CO2laser. J Cosmet Laser Ther. 2011;14(1):43–47.
   Web of Science ®Google Scholar
• Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv Drug Deliv Rev. 1999;35(1):107–118.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008;15(8):2215–2222.
   PubMed Web of Science ®Google Scholar
• Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol. 2009;16(1):191–199.
   PubMed Web of Science ®Google Scholar
• Kis E, OlÁH J, ÓCsai H, et al. Electrochemotherapy of cutaneous metastases of melanoma-a case series study and systematic review of the evidence. Dermatol Surg. 2011;37(6):816–824.
   PubMed Web of Science ®Google Scholar
• Solari N, Spagnolo F, Ponte E, et al. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. J Surg Oncol. 2013;109(3):270–274.
   PubMed Web of Science ®Google Scholar
• Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. 2012;99(6):821–830.
   PubMed Web of Science ®Google Scholar
• Campana LG, Testori A, Curatolo P, et al. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. EJSO. 2016;42(12):1914–1923.
   PubMed Web of Science ®Google Scholar
• Colombo G. Cost-effectiveness analysis of electrochemotherapy with the cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag. 2008;4:541–548.
   PubMedGoogle Scholar
• Mozzillo N, Caracò C, Mori S, et al. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012;10(1):131.
   PubMedGoogle Scholar
• Gerlini G, Di Gennaro P, Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. OncoImmunology. 2012;1(9):1655–1657.
   PubMed Web of Science ®Google Scholar
• Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet. 1989;334(8660):445.
   Google Scholar
• Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56(5):869–871.
   PubMed Web of Science ®Google Scholar
• Damian DL, Saw RPM, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2013;109(4):308–313.
   PubMed Web of Science ®Google Scholar
• Read T, Webber S, Tan J, et al. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study. J Eur Acad Dermatol Venerol. 2017;31(12):2030–2037.
   PubMed Web of Science ®Google Scholar
• Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205(2):135–138.
   PubMed Web of Science ®Google Scholar
• Sisti A, Sisti G, Oranges CM. Topical treatment of melanoma skin metastases with imiquimod: a review. Dermatol Online J. 2014;21(2).
   PubMedGoogle Scholar
• Joseph RW, Cappel M, Tzou K, et al. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Res. 2016;26(4):409–412.
   PubMed Web of Science ®Google Scholar
• Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994;30(4):795–798.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg. 1995;19(3):369–371.
   PubMed Web of Science ®Google Scholar
• Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol. 1995;2(5):445–449.
   PubMed Web of Science ®Google Scholar
• Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004;100(2):383–389.
   PubMed Web of Science ®Google Scholar
• Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64(1):106–113.
   PubMed Web of Science ®Google Scholar
• Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J. 2012;18(2):203–207.
   PubMed Web of Science ®Google Scholar
• Bornstein RS, Mastrangelo MJ, Sulit H, et al. Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr. 1973;39:213–220.
   PubMedGoogle Scholar
• Morton DL, Eilber FR, Holmes EC, et al. BCG lmmunotherapy of malignant melanoma. Ann Surg. 1974;180(4):635–643.
   PubMed Web of Science ®Google Scholar
• Gutwald JGJ, Groth W, Mahrle G. Perilumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br J Dermatol. 1994;130(4):541–542.
   PubMed Web of Science ®Google Scholar
• Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2. Cancer. 2010;116(17):4139–4146.
   PubMed Web of Science ®Google Scholar
• Boyd KU, Wehrli BM, Temple CLF. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011;104(7):711–717.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18(6):405–411.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Neuberg D, Park Y, et al. Mature results of a phase III randomized trial of Bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American joint committee on cancer stage I-III melanoma (E1673). Cancer. 2004;100(8):1692–1698.
   PubMed Web of Science ®Google Scholar
• Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 2012;35(9):716–720.
   PubMed Web of Science ®Google Scholar
• Byers BA, Temple-Oberle CF, Hurdle V, et al. Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review. J Surg Oncol. 2014;110(6):770–775.
   PubMed Web of Science ®Google Scholar
• Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015;73(4):645–654.
   PubMed Web of Science ®Google Scholar
• Pretto F, Elia G, Castioni N, et al. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother. 2014;63(9):901–910.
   PubMed Web of Science ®Google Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135–2142.
   PubMed Web of Science ®Google Scholar
• Den Brok MHMGM, Sutmuller RPM, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024–4029.
   PubMed Web of Science ®Google Scholar
• Toomey P, Kodumudi K, Weber A, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2013;8(7):e68561.
   PubMed Web of Science ®Google Scholar
• Foote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res. 2010;20(1):48–51.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor–encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169–4177.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Curti BD, Hallmeyer S, et al. Phase II calm extension study; coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. J Immunother Cancer. 2015;3(Suppl 2):P343.
   Google Scholar
• Creech O Jr., Ryan RF, Krementz ET. Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc. 1959;169(4):339–343.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–192.
   Google Scholar
• Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA. 1985;82(16):5328–5331.
   PubMed Web of Science ®Google Scholar
• Nieweg OE, Kroon BBR. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol. 2014;109(4):332–337.
   PubMed Web of Science ®Google Scholar
• Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15(4):416–427.
   PubMed Web of Science ®Google Scholar
• Kroon HM, Huismans AM, Kam PCA, et al. Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review. J Surg Oncol. 2014;109(4):348–351.
   PubMed Web of Science ®Google Scholar
• Miura JT, Kroon HM, Beasley GM, et al. Long-term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis. Ann Surg Oncol. 2019;26(8):2486–2494.
   PubMed Web of Science ®Google Scholar
• Turnbull A, Shah J, Fortner J. Recurrent melanoma of an extremity treated by major amputation. Arch Surg. 1973;106(4):496–498.
   PubMedGoogle Scholar
• Kourtesis GJ, McCarthy WH, Milton GW. Major amputations for melanoma. Aust NZ J Surg. 1983;53(3):241–244.
   PubMedGoogle Scholar
• Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet. 1989;169(1):1–6.
   PubMedGoogle Scholar
• Ebskov LB. Major amputation for malignant melanoma: an epidemiological study. J Surg Oncol. 1993;52(2):89–91.
   PubMed Web of Science ®Google Scholar
• Kapma MR, Vrouenraets BC, Nieweg OE, et al. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol. 2005;31(1):95–99.
   PubMed Web of Science ®Google Scholar
• Kroon HM, Lin DY, Kam PC, et al. Major amputation for irresectable extremity melanoma after failure of isolated limb infusion. Ann Surg Oncol. 2009;16(6):1543–1547.
   PubMed Web of Science ®Google Scholar
• Read RL, Stalley P, Thompson JF. The contemporary role of major amputation in the management of advanced limb melanoma. Ann Surg Oncol. 2015;22(12):4067–4072.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2016;96(3):578–588.
   PubMed Web of Science ®Google Scholar
• Mohamad O, Diaz de Leon A, Schroeder S, et al. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. OncoImmunology. 2018;7(7):e1440168.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Almutairi AR, Alkhatib NS, Oh M, et al. Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma. JAMA Dermatol. 2019;155(1):22.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Ross M. The importance of outcome and precise evaluation in economic analysis of cancer drugs. JAMA Dermatol. 2019;155(7):862–863.
   PubMedGoogle Scholar
• Dudek-Peri AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75(8):1603–1614.
   PubMed Web of Science ®Google Scholar
• Ariyan CE, Brady MS, Siegelbaum RH, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6(2):189–200.
   PubMed Web of Science ®Google Scholar